Peter Wolpert, founder and CEO of Moberg Pharma, has divested 164,601 shares in Moberg Pharma and remains large long-term shareholder
Following the divestment, Peter Wolpert holds 435,399 shares, remaining one of the ten largest shareholders in the company. Furthermore, he holds stock options entitling him to subscribe for another 125,000 shares.
The divestment is made for personal financial reasons and I don’t intend to sell additional shares.
“I have great faith in the prospects for Moberg Pharma and I look forward to continuing to build the company.”
Moberg Pharma is a growing Swedish pharmaceutical company with OTC sales operations in the US and a distributor network in more than 40 countries.
The company’s portfolio includes the OTC brands Kerasal, Kerasal Nail, Balmex, NewSkin, DermoPlast, Domeboro and Fiber Choice. Kerasal Nail (Emtrix or Nalox in certain markets) is an OTC treatment of nail disorders in the US, Canada and several markets in EU and Southeast Asia.